Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen
- 1 July 1998
- journal article
- clinical trial
- Published by Wolters Kluwer Health in AIDS
- Vol. 12 (11) , 1291-1300
- https://doi.org/10.1097/00002030-199811000-00010
Abstract
To evaluate the safety and immunogenicity of a polyvalent (PV) HIV envelope synthetic peptide immunogen, C4-V3. The immunogen comprised four peptides containing T-helper epitopes from the fourth constant region (C4) of gp120 of HIV-1MN, and T-helper, cytotoxic T-lymphocyte HLA-B7-restricted, and B-cell neutralizing epitopes from the gp120 third variable region (V3) of four clade B HIV-1 isolates, HIV-1MN, HIV-1RF, HIV-1EV91, and HIV-1Can0A. A pilot, Phase I controlled trial [Division of AIDS Treatment Research Initiative (DATRI) 010] conducted at a single center. Ten HIV-infected, HLA-B7-positive patients with CD4 cells > 500 x 10(6)/l were enrolled. Eight patients received the C4-V3 PV immunogen emulsified in incomplete Freund's adjuvant in five intramuscular injections over 24 weeks, and two controls received incomplete Freund's adjuvant alone. All subjects were followed for 52 weeks. Four out of eight C4-V3 PV recipients generated at least fourfold rise in serum antibody titers to at least three immunogen peptides in contrast to none of the control subjects. Four out of eight C4-V3 PV recipients and none of the controls had an at least fourfold rise in neutralizing antibodies to either HIV-1MN, HIV-1RF, or HIV-1(4489-5) laboratory-adapted HIV isolates. 3H-Thymidine incorporation assays of peripheral blood mononuclear cells increased at least fivefold over the baseline stimulation index to at least one of the immunogen peptides in two consecutive post-immunization timepoints in five out of eight C4-V3 PV recipients versus none of the controls. CD4 cell counts and plasma HIV RNA levels did not change in patients who received either C4-V3 PV or adjuvant alone. Adverse events consisted primarily of grade 1 injection site reactions in six subjects (four C4-V3 recipients, two controls). C4-V3 PV synthetic peptides demonstrated both immunogenicity and safety in HIV-infected patients.Keywords
This publication has 23 references indexed in Scilit:
- Safety and Immunogenicity of UBI HIV-1MNOctameric V3 Peptide Vaccine Administered by Subcutaneous InjectionAIDS Research and Human Retroviruses, 1997
- Effect of Immunization with a Common Recall Antigen on Viral Expression in Patients Infected with Human Immunodeficiency Virus Type 1New England Journal of Medicine, 1996
- Safety and immunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative volunteersAIDS, 1995
- HIV Type 1 V3 Region Primer-Induced Antibody Suppression Is Overcome by Administration of C4-V3 Peptides as a Polyvalent ImmunogenAIDS Research and Human Retroviruses, 1995
- NMR-Derived Solution Conformations of a Hybrid Synthetic Peptide Containing Multiple Epitopes of Envelope Protein gp120 from the RF Strain of Human Immunodeficiency VirusBiochemistry, 1994
- Augmentation of Human Immunodeficiency Virus Type 1 Neutralizing Antibody by Priming with gp160 Recombinant Vaccinia and Boosting with gp160 in Vaccinia-Naive AdultsThe Journal of Infectious Diseases, 1993
- A Phase I Evaluation of the Safety and Immunogenicity of Vaccination with Recombinant gp160 in Patients with Early Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1991
- Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.Proceedings of the National Academy of Sciences, 1988
- Cellular Immune Response to Viral Peptides in Patients Exposed to HIVAIDS Research and Human Retroviruses, 1988